Can patients with obstructive sleep apnea titrate their own continuous positive airway pressure?

Manual continuous positive airway pressure (CPAP) titration in a sleep laboratory is costly and limits access for diagnostic studies. Many factors affect CPAP compliance, but education and support, rather than in-laboratory CPAP titration, appear to be pivotal. Self-adjustment of CPAP at home will provide equal or superior efficacy in the treatment of obstructive sleep apnea (OSA) as compared with in-laboratory titration. A randomized, single-blind, two-period crossover trial of CPAP treatment at the in-laboratory-determined optimal pressure versus at-home self-adjustment of CPAP (starting pressure based on prediction equation). Eighteen CPAP-naive patients (16 males, 50 +/- 15 years old, apnea hypopnea index 40 +/- 20) with a new diagnosis of OSA were tested. Testing was performed before and after CPAP treatment in each of two 5-week study limbs. CPAP, compliance with CPAP treatment, the Sleep Apnea Quality of Life Index, the Functional Outcomes of Sleep Questionnaire score, the Epworth sleepiness scale score, sleep architecture, sleep apnea severity, and maintenance of wakefulness tests were performed. Both modes of CPAP treatment significantly improved objective and subjective measures of OSA, but they did not differ in efficacy. Home self-titration of CPAP is as effective as in-laboratory manual titration in the management of patients with OSA.     

Effects of continuous positive airway pressure on apnea–hypopnea index in obstructive sleep apnea based on long-term compliance

Purpose  

Although continuous positive airway pressure (CPAP) is the gold standard in the treatment of obstructive sleep apnea (OSA), its effectiveness depends on the regular use. In this retrospective study, the effectiveness of CPAP with regard to the reduction of the apnea–hypopnea index was calculated based on individual adherence data extracted from a cohort of patients with OSA     

Does continuous positive airway pressure reduce aldosterone levels in patients with obstructive sleep apnea?

Purpose

Aldosterone is associated with the development of obstructive sleep apnea (OSA) and cardiovascular diseases. Continuous positive airway pressure (CPAP) is an effective treatment for OSA, but the impact of CPAP therapy on aldosterone levels in patients with OSA remains unclear. To address this issue, a meta-analysis was conducted to evaluate the effects of CPAP therapy on serum aldosterone levels in OSA.

Methods

Two reviewers independently searched PubMed, Cochrane library, Embase, and Web of Science before March 2015. Information on characteristics of subjects, study design, and pre- and post-CPAP treatment of serum aldosterone was extracted for analysis. Standardized mean difference (SMD) was calculated to estimate the treatment effects of CPAP therapy.

Results

A total of 5 studies involving 329 patients were pooled into this meta-analysis, including 3 observational studies and 2 randomized controlled studies. Results indicated significantly decreased aldosterone levels after CPAP therapy (SMD?=??0.236, 95 % confidence interval (CI)?=??0.45 to ?0.02, z?=?2.12, p?=?0.034).

Conclusions

This meta-analysis suggested that CPAP therapy was associated with a decrease in serum aldosterone in patients with OSA. Further large-scale, well-designed interventional investigations are needed to clarify this issue.

     

Do obstructive sleep apnea syndrome patients underestimate their daytime symptoms before continuous positive airway pressure treatment?

BACKGROUND:

Daytime somnolence is an important feature of the obstructive sleep apnea (OSA) hypopnea syndrome and is usually subjectively assessed using the Epworth Sleepiness Scale (ESS).

OBJECTIVE:

To compare the scores of the ESS and different domains of the Quebec Sleep Questionnaire (QSQ) assessed before and after the first months of continuous positive airway pressure (CPAP) treatment, as well as retrospectively without treatment.

METHODS:

The ESS score and domain scores of the QSQ were obtained before and after a three-month period of CPAP treatment using a retrospective assessment of the pretreatment scores in 76 untreated OSA patients.

RESULTS:

Fifty-two patients completed the study. The ESS and QSQ scores significantly improved following CPAP therapy. Retrospective evaluation of the ESS score was significantly worse than pre- and post-treatment values (mean [± SD] pretreatment score 11.0±4.8; retrospective pretreatment score 13.5±5.1). Such differences were not observed in any domain of the QSQ, including the domain assessing hypersomnolence.

CONCLUSION:

OSA patients underestimated their sleepiness according to the most widely used instrument to assess hypersomnolence. This finding may not be observed with other methods used to assess OSA-related symptoms such as quality of life questionnaires.     

Can continuous positive airway pressure therapy improve the general health status of patients with obstructive sleep apnea?: a clinical effectiveness study

STUDY OBJECTIVES: To determine the short-term and long-term impacts of continuous positive airway pressure (CPAP) therapy on health-related quality of life (HRQL) in patients with obstructive sleep apnea (OSA). DESIGN: Prospective longitudinal cohort study. SETTING: University sleep disorders center. PATIENTS: Three hundred sixty-five patients with an apnea-hypopnea index (AHI) > or = 20 per hour of sleep and 358 patients with an AHI of < 20. INTERVENTIONS: All patients with AHIs > or = 20 received CPAP therapy; those with AHIs < 20 did not. The HRQL of all study participants was measured using the 36-item medical outcomes study short form (SF-36) questionnaire at baseline and then at 3 and 12 months of follow-up. RESULTS: Although the SF-36 scores were similar at baseline, after 3 months of therapy, the CPAP group had higher adjusted emotional summary scores than did those who did not receive CPAP therapy (score increase, 1.72; 95% confidence interval [CI], 0.08 to 3.37). These improvements were maintained for 12 months. The gains in the SF-36 scores were most striking in the vitality domain (score increase, 10.52; 95% CI, 7.04 to 14.00 U increment). The severe OSA group (ie, AHIs > or = 40) experienced the largest benefit. Their adjusted vitality scores were 12.3 U higher (95% CI, 8.0 to 16.6) than those persons without OSA (ie, AHIs < 5). CONCLUSIONS: CPAP therapy was associated with marked short-term and long-term improvements in the vitality of patients with moderate-to-severe OSA in the community. These findings suggest that CPAP therapy is effective in improving the long-term HRQL of patients with OSA.     

Should flow-volume loop be monitored in sleep apnea patients treated with continuous positive airway pressure?

Nasal continuous positive airway pressure (nCPAP) has been widely established in the treatment of obstructive sleep apnea syndrome (OSAS). However, only few studies have evaluated long-term effects of this treatment on lung function. This study assesses the effect of nCPAP on lung function parameters and response to bronchodilators in 50 OSAS patients. Spirometry and arterial blood gas measurements were performed before starting nCPAP and after 16.8 +/- 8 months of treatment. Of the 50 study patients (55 +/- 12 years, with an apnea/hypopnea index of 47 +/- 34h(-1)), 15 had asthma, 13 had chronic obstructive pulmonary disease (COPD) and 22 had no obstructive airway disease (NOAD). In the entire population, significant decreases in FEF50 (from 69 +/- 38% to 61 +/- 30%, P < 0.005), FEF25 (from 53 +/- 34% to 46 +/- 28%, P < 0.05) and FEF25-75 (from 65 +/- 33% to 57 +/- 27%, P < 0.005) were observed after treatment. No impairment of lung function was found in COPD and asthmatic patients. In contrast, lung function was changed in the NOAD group where FEF50, FEF25 and FEF25-75 as well as FEV1 and FEV1/VC ratio were significantly reduced. Moreover, bronchial hyperresponsiveness occurred in five of 22 patients of this group. These results suggest that tolerance of nCPAP should be handled by long-term follow-up of flow-volume loops.     

Which derivative from overnight oximetry best predicts symptomatic response to nasal continuous positive airway pressure in patients with obstructive sleep apnoea?

The cost and inconvenience of polysomnography for the investigation of obstructive sleep apnoea (OSA) has led to the search for simpler and cheaper alternatives. These are usually compared to an apnoea/hypopnoea index (AHI) derived from oro-nasal airflow and ribcage/abdominal effort sensors. However, AHI is not a proven gold standard for the identification of clinically important OSA. Recent work has shown that correctly analysed oximetry indices not only mimic AHI with considerable accuracy, but also predict the symptomatic response to nasal continuous positive airway pressure (nCPAP) at least as well as conventional polysomnographic indices. This current study looks at 10 different derivatives of all-night oximeter tracings in 81 patients with OSA, and compares their ability to predict the improvement in subjective sleepiness after 6 months of nCPAP therapy. Sleep apnoea in this study was defined as a > 4% SaO2 dip rate of > 10 h(-1), and an Epworth sleepiness score (ESS) of > 10 on presentation. Subjects took part in a placebo-controlled trial of nCPAP for 1 month and thereafter were all supplied with nCPAP set at an effective pressure. All night SaO2 was sampled every 2 sec and later analysed for mean, median, mean nadir of SaO2 dip, time below 90%, 2 and 12 sec delta index (an average measure of SaO2 change across these two time periods), rapid resaturation index (rises in SaO2 > 3% within 10 sec per hour), and > 4, > 3, and > 2% dips per hour. These indices were then correlated with the change in ESS seen after 6 months on nCPAP. Median compliance for the group was 5.8 (5/95% range, 1.5-8.0) h night(-1). The two best correlates of improvement in ESS were the > 4% SaO2 dips h(-1) (Spearman's r = -0.33 P=0.002) and the delta 12 sec index (r = -0.33, P = 0.003). Cumulative time below 90% SaO2 was almost as good (r = -0.29, P = 0.009). The worst correlate was the > 2% SaO2 dips h(-1) (r = 0.01, not significant). This study has identified which of several analyses of overnight oximeter recordings best identify nCPAP responsive OSA. Both > 4% SaO2 dips and 12 sec delta index are equally predictive and presumably the most appropriate derivatives to calculate from overnight records of SaO2.     

Established vascular effects of continuous positive airway pressure therapy in patients with obstructive sleep apnoea—an update

The aim of this review was to summarize the current data from randomised controlled trials (RCTs) on vascular effects of continuous positive airway pressure (CPAP) therapy in patients with obstructive sleep apnoea (OSA). There is good evidence from RCTs that CPAP lowers blood pressure (BP) to a clinically significant amount. The effect seems to be dependent on the hours of nightly CPAP usage. Data from RCTs have also proven a beneficial effect of CPAP on measures of vascular function such as endothelial function and arterial stiffness. However, there is still a lack of evidence from RCTs proving that CPAP reduces vascular events and mortality.     

Positive airway pressure therapy for chronic pain in patients with obstructive sleep apnea—a systematic review

Purpose

Obstructive sleep apnea (OSA) is prevalent in patients with chronic non-cancer pain. OSA may lead to low sleep quality and an increase in pain sensitivity. Patients reporting greater sleep impairment tend to experience higher pain intensity and vice versa. Positive airway pressure (PAP) is the current gold standard treatment for OSA. This review aims to evaluate the efficacy of PAP therapy in patients with comorbid chronic pain and OSA in influencing pain outcomes like pain intensity, tolerance, threshold, and sensitivity.

Methods

We performed a systematic literature search for studies published after 1990, utilizing the following databases: Medline, Medline In-Process/ePubs, Embase, Cochrane CENTRAL, and the Cochrane Database of Systematic Reviews. Search terms included “chronic pain,” “sleep disorders,” and “positive airway pressure.”

Results

Of 1982 initial studies, ten studies met the study inclusion criteria. Seven of these studies examined the effect of PAP therapy on chronic pain, of which five demonstrated improved pain outcomes, specifically, headache pain. The effect of PAP therapy on chronic non-headache pain was found to be inconclusive. When examining the three studies that did not involve chronic pain patients, PAP therapy effectively increased pain threshold and tolerance in two studies (p = 0.03 and p = 0.01).

Conclusion

An association exists between PAP therapy and decreased chronic headache outcomes in patients with OSA. Additionally, research shows that PAP therapy may increase pain tolerance and threshold. Future high-quality evidence is required to further investigate the association between PAP and non-headache chronic pain.

     

Can drug-induced sleep endoscopy (DISE) predict compliance with positive airway pressure therapy? A pilot study

Purpose

Drug-induced sleep endoscopy (DISE) has been poorly explored as an examination to assess positive airway pressure (PAP) therapy in patients with obstructive sleep apnea (OSA). The present study aimed to identify by DISE possible characteristics related to low compliance with PAP therapy due to respiratory complaints.

Methods

Patients using PAP for OSA underwent DISE in two conditions: (1) baseline (without PAP) and (2) PAP (with the same mask and airway pressure used at home). We compared patients reporting low compliance to PAP due to respiratory complaints to those well-adapted to therapy. VOTE classification (assessment of velopharynx, oropharynx, tongue base, and epiglottis) and TOTAL VOTE score (the sum of VOTE scores at each anatomical site) were assessed. ROC curve analyzed the accuracy of TOTAL VOTE to predict low compliance due to persistent pharyngeal obstruction in both conditions.

Results

Of 19 patients enrolled, all presented multilevel pharyngeal obstruction at baseline condition, with no difference between groups at this study point. When PAP was added, the median VOTE value was higher in the epiglottis (P value=0.02) and tended to be higher at the velum and tongue base in the poorly adapted group; TOTAL VOTE score was also significantly increased in patients with low compliance (P value<0.001). ROC curve demonstrated that patients with TOTAL VOTE scored 2.5 or more during DISE with PAP presented a 4.6-fold higher risk for low compliance with PAP therapy due to pharyngeal obstruction (AUC: 0.88±0.07; P value<0.01; sensitivity: 77%; specificity: 83%).

Conclusions

Adding PAP during a DISE examination may help to predict persistent pharyngeal obstruction during PAP therapy.